Webinar Overview
Demand is increasing for chemical screening solutions to address carcinogenicity, mutagenicity, and reproductive toxicity (CMR) and endocrine disruption (ED) potential of new and existing compounds. These screening packages will help you manage your portfolio and development pipeline by profiling compounds at an early stage to predict any public and environmental risks.
Using new approach methodologies (NAMs), CMR and ED predictions can be made providing you with alternatives for efficient and accurate data as well as an opportunity to replace potentially risky or problematic compounds earlier.
In this webinar you will gain insights including:
- How chemical companies can use CMR and ED safety screening to identify red flags early
- The cost and time saving benefits of screening programs
- Examples of studies used including in vitro and in silico methods
- Discussion on the merits of NAMs versus animal studies
Webinar Presenters
Ilse Tonk, PhD, ERT
Senior Principal Regulatory Toxicologist
Charles River
Bas-jan van der Leede, PhD
Senior Principal Research Scientist, Flexible Innovation Team, Discovery & Environmental Sciences
Charles River
Mira Wenker, PhD
Section Head, Drug Metabolism and Pharmacokinetics
Charles River